Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.65 |
| ▸ | NCOR1 | O75376 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 4/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.55 |
| ▸ | KDR | P35968 | 4/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584418 | 0.90 | HDAC1 (0.68) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL1064065 | 0.82 | HDAC1 (0.60) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL210811 | 0.81 | HDAC1 (0.66) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL212577 | 0.81 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| Mocetinostat SCHEMBL29454790 | 0.78 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| Mocetinostat SCHEMBL29534132 | 0.78 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| Mocetinostat SCHEMBL157027 | 0.78 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| Mocetinostat SCHEMBL29379811 | 0.78 | HDAC1 (0.98) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL5227360 | 0.78 | HDAC1 (0.71) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL4086310 | 0.77 | HDAC1 (0.84) | HDAC1HDAC2HDAC3HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | claimed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | claimed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | HDAC1 1/4885HDAC2 8/4885HDAC3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.